Skip to content

Wednesday, 11 November 2026

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

From The Motley Fool 11 Nov 2026, 20:00 UTC 1 min read

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027? — Image: The Motley Fool

Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.

Full story

Continue reading this story on The Motley Fool, the publisher that reported it.

Read the full story at The Motley Fool ↗

AI tools

Written by AI from the article text. It can make mistakes; check the original story.

Topics in this story

More from Business

See all

Business

This Triple Tax-Advantaged Retirement Account Should Not Be Overlooked

33 min ago

Business

Why the data center you dread might never even be built

34 min ago

Business

Meta is losing its longtime head of infrastructure

37 min ago

Business

Robinhood Markets vs. Sezzle: Which Financial Stock Is a Better Buy for 2027?

38 min ago

Business

Could Marvell’s $115 Billion Gamble Become Its Greatest Advantage?

42 min ago

Business

Lucid Recalled 4,400 Gravity SUVs, Delayed the Cosmos, and Is "Buying Time." Here's How Many Shares It Needs to Sell to Survive 2027.

44 min ago